Skip to main content
. 2017 Sep 21;8:637. doi: 10.1038/s41467-017-00576-7

Fig. 3.

Fig. 3

In vivo expression of DMAb-αPcrV and DMAb-BiSPA in mice. a B6.Cg-Foxn1 < nu > /J mice (n = 5/group) were administered 100 µg of DMAb-αPcrV by IM-EP. Serum levels of human IgG were monitored over 120 days. b Day 7 serum levels in BALB/c mice (n = 10/group) administered 100 and 300 µg for DMAb-αPcrV. The line represents the mean value. c Day 7 serum binding to PcrV protein in BALB/c mice (n = 10/group) administered 100 µg of DMAb-αPcrV. d B6.Cg-Foxn1 < nu > /J mice (n = 5/group) were administered 100 µg of DMAb-BiSPA by IM-EP. Serum levels of human IgG were monitored over 120 days. e, b Day 7 serum levels in BALB/c mice (n = 10/group) administered 100 and 300 µg for DMAb-BiSPA. The line represents the mean value. f Day 7 serum binding to PcrV protein in BALB/c mice (n = 10/group) administered 100 µg of DMAb-BiSPA